ClinicalTrials.gg
RecruitingNCT01885299Updated Sep 19, 2024

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

An observational study in Neoplasms, Arteriovenous Malformation of Central Nervous System and Trigeminal Neuralgia, sponsored by The Radiosurgery Society. Recruiting at 13 sites in United States. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by The Radiosurgery Society · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
50,000
Sex
All
01

Study summary

The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)

Read the detailed description

The Registry is designed to help SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) users to understand utilization of and key treatment outcomes for these treatment approaches. Some of the objectives include:

Allow participants to record information about usage of SRS/SBRT in everyday practice, including patient characteristics and disease information, treatment plans and outcomes Provide participants with ready access to data for publication of their own experience and as a tool for establishing collaborations with other participating sites Facilitate quality improvement efforts for individual treatment providers Understand the effectiveness of different treatment plans for different types of lesions, diseases and treatments

The Registry tracks select outcomes for each condition treated by SRS/SBRT (for example, PSA for prostate cancer); the Registry also provides individual participants the ability to add additional outcomes for each and any condition of specific interest to their institutions.

The Registry is hosted by Vision Tree, Inc who is an independent vendor of electronic registries; they are responsible for HIPAA compliance, including all security mechanisms.

Patients will be enrolled prospectively. Some retrospective patient data is likely to be included in order to capture both short and longer term outcomes data.

02

Conditions studied

  • Neoplasms
  • Arteriovenous Malformation of Central Nervous System
  • Trigeminal Neuralgia

Keywords

  • Radiosurgery
  • CyberKnife
  • Benign tumors
  • Malignant tumors
  • Cranial tumors
  • Extracranial tumors
  • Lung
  • Liver
  • Pancreas
  • Prostate
  • Stereotactic radiosurgery
  • Stereotactic body radiotherapy
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 50,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with The Radiosurgery Society as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patients who have a SRS/SBRT procedure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of benign or malignant tumors or other conditions deemed treatable by stereotactic radiosurgery or stereotactic body radiotherapy
  • Willingness to sign an Document or verbally agree to participation

Exclusion criteria

Exclusion Criteria:

  • There are no specific exclusion criteria, but patients who are unwilling to sign the ICD or who decline participation will not be included
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
50,000 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Groups and cohorts

  • Patients being treated by SRS/SBRT

    Patients with a condition being considered for treatment by SRS/SBRT

    Radiation: SRS/SBRT

Interventions

  • RadiationSRS/SBRT

    Intervention varies by condition being treated.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Survival from time of treatment to death

    Time frame: Up to 5 years

Secondary outcomes

  1. Local and distant recurrence

    Calculated from time of treatment to recurrence

    Time frame: One to Five years

Other outcomes

  1. Treatment toxicity

    Complications of treatment. These complications are organ specific depending on which organ is being treated. For example, if the prostate is being treated,there may be rectal and urinary complications. If the brain is being treated, there may be headaches or nausea. The Radiation Therapy Oncology Group (RTOG) scale used for defining and measuring complications of radiotherapy is incorporated into the Registry database.

    Time frame: Immediate -5 years

07

Study locations

13 of 13 sites recruiting
  • Penrose Cancer Center
    Colorado Springs, Colorado 80907, United States
    Enrolling by invitation
  • Sylvester Comprehensive Cancer Center, University of Miami
    Miami, Florida 33146, United States
    Recruiting
  • Southeast Georgia Health System
    Brunswick, Georgia 31520, United States
    Enrolling by invitation
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
    Recruiting
    • Celina Kirsch, P.A. · ContactCKirsch2@hfhs.org · 313-640-2345
    • Parag Parikh, M.D. · Principal investigator
  • AtlantiCare Regional Medical Center and AtlantiCare Cancer Care Institute
    Egg Harbor Township, New Jersey 08234, United States
    Enrolling by invitation
  • Riverview Medical Center
    Red Bank, New Jersey 07701, United States
    Enrolling by invitation
  • NJ Cyberknife at Community Medical Center
    Toms River, New Jersey 08755, United States
    Enrolling by invitation
  • Montefiore Medical Center
    Bronx, New York 10502, United States
    Enrolling by invitation
  • Geisinger Health System
    Danville, Pennsylvania 17822, United States
    Enrolling by invitation
  • Philadelphia CyberKnife
    Philadelphia, Pennsylvania 19083, United States
    Enrolling by invitation
  • Pottstown Memorial Medical Center
    Pottstown, Pennsylvania 19464, United States
    Enrolling by invitation
  • Cyberknife at Erlanger
    Chattanooga, Tennessee 37403, United States
    Enrolling by invitation
  • St. Mary's Medical Center
    Huntington, West Virginia 25701, United States
    Enrolling by invitation
08

References and documents

Publications

  • Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, Schoelles KM. Stereotactic Body Radiation Therapy [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 10(11)-EHC058-EF. Available from http://www.ncbi.nlm.nih.gov/books/NBK55723/ PubMed 21735562 ↗
  • Dieterich S, Gibbs IC. The CyberKnife in clinical use: current roles, future expectations. Front Radiat Ther Oncol. 2011;43:181-194. doi: 10.1159/000322423. Epub 2011 May 20. PubMed 21625154 ↗
  • Wowra B, Muacevic A, Tonn JC. CyberKnife radiosurgery for brain metastases. Prog Neurol Surg. 2012;25:201-9. doi: 10.1159/000331193. Epub 2012 Jan 6. PubMed 22236681 ↗
  • Sarwate D, Sarkar S, Krimsky WS, Burgan CM, Patel K, Evans R, Harley DP. Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest. J Thorac Cardiovasc Surg. 2012 Jul;144(1):81-6. doi: 10.1016/j.jtcvs.2012.03.004. Epub 2012 Apr 11. PubMed 22498085 ↗
  • Sohn S, Chung CK. The role of stereotactic radiosurgery in metastasis to the spine. J Korean Neurosurg Soc. 2012 Jan;51(1):1-7. doi: 10.3340/jkns.2012.51.1.1. Epub 2012 Jan 31. PubMed 22396835 ↗
  • Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, Muacevic A, Mahadevan A. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch((R)) patient registry. Radiat Oncol. 2015 May 15;10:113. doi: 10.1186/s13014-015-0417-5. PubMed 25975848 ↗
  • Davis JN, Medbery C 3rd, Sharma S, Perry D, Pablo J, D'Ambrosio DJ, McKellar H, Kimsey FC, Chomiak PN, Mahadevan A. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol. 2015;4(1):55-63. doi: 10.1007/s13566-014-0177-0. Epub 2015 Jan 31. PubMed 25774243 ↗
  • Davis JN, Medbery C 3rd, Sharma S, Danish A, Mahadevan A. The RSSearch Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol. 2013 Nov 25;8:275. doi: 10.1186/1748-717X-8-275. PubMed 24274599 ↗
  • Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, D'Ambrosio D, Sharma S, Sundararaman S, Kolker J, Creach KM, Lanciano R. Lung metastases treated with stereotactic body radiotherapy: the RSSearch(R) patient Registry's experience. Radiat Oncol. 2017 Feb 1;12(1):35. doi: 10.1186/s13014-017-0773-4. PubMed 28143558 ↗
  • Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395. PubMed 26798571 ↗
  • Singh R, Davis J, Sharma S. Stereotactic Radiosurgery for Trigeminal Neuralgia: A Retrospective Multi-Institutional Examination of Treatment Outcomes. Cureus. 2016 Apr 3;8(4):e554. doi: 10.7759/cureus.554. PubMed 27182468 ↗
  • Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D'Ambrosio D, Sharma S, Perry D, Kolker J, Davis J. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat Oncol. 2018 Feb 13;13(1):26. doi: 10.1186/s13014-018-0969-2. PubMed 29439707 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Dec 2030 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2013
First posted
Jun 24, 2013
Start
Mar 2012
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01885299
Lead sponsor
The Radiosurgery Society
Collaborators
VisionTree
Responsible party
Sponsor
First posted
Jun 24, 2013
Start date
Mar 2012
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Sep 19, 2024

Study contacts

Jan Jenkins, RN
Contact
jjenkins@therss.org
Joanne Davis, PHD
Contact
jdavis@therss.org
Anand Mahadevan, MD
study director · The Radiosurgery Society

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion